所有者依赖首先是估值问题，其次才是生活方式问题，且需按特定顺序解决。 数字健康公司在此面临特定困境——结果风险的承担速度快于公司能否判断自身能否承受的速度，12个月的测量窗口对上11个月的销售周期。在此定价前，风险收入分成将继续因无人能归因的原因而变动，而关于是否需要所有者决策的争论仍将只是意见之争。
所有者依赖首先是估值问题，其次才是生活方式问题，且需按特定顺序解决。 数字健康公司在此面临特定困境——结果风险的承担速度快于公司能否判断自身能否承受的速度，12个月的测量窗口对上11个月的销售周期。在此定价前，风险收入分成将继续因无人能归因的原因而变动，而关于是否需要所有者决策的争论仍将只是意见之争。
每家创始人主导的数字健康公司起步时都存在所有者依赖；问题在于依赖是否在减少。三类依赖重要且按固定顺序解除：关系依赖、决策依赖和知识依赖。
关系最难且最先解除，因为转移耗时最长——付款方转至另一关系持有者，需要多个测量窗口才能真正转移归属结果。决策其次，主要在于明确已隐性应用的按风险分成或PMPM条款规则。知识最后，主要是记录参与率和毛利率驱动因素。
失败模式是从文档化开始，因为这感觉有成效，最终形成一家文档完备但仍无法在没有所有者的情况下续签风险合同或留住客户的业务。
在数字健康领域，CEO或CFO往往仍需参与每份风险收入分成协议及每家因结果面临流失风险的客户。这属于关系依赖，而非缺失流程文件。与任何承担结果风险的创始人主导公司顺序相同：先转移付款方和会员关系。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 关于风险分成或参与门槛的重大决策需等待一人
✓ 关键客户若创始人离职会跟随个人而非企业
✓ 离开业务一段时间，客户流失或测量窗口实际受影响
通常会让情况更糟的做法。 在风险收入决策规则存在前聘用总经理，将某人引入尚未定义的职位。
It is for you if you run or finance a digital health company and meaningful decisions wait for one person. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家数字健康公司. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Vantabridge Health, a sample company profile used for testing rather than a customer — $62M ARR, 340,000 enrolled members.
Excerpt from a real Percision run · Competitive Positioning · sample company profile
The move. Monetize the largest three-condition outcomes dataset to subsidize outcomes risk and generate 13% growth without increasing at-risk share.
The leak it closes. Reduces dependence on 38% at-risk PMPM revenue by adding non-at-risk, high-margin revenue stream
The assumption it rests on. State privacy laws do not mandate patient-level consent for de-identified data before 2029 — the engine put the probability at 0.7.
| Investment required | $1.8–2.4M over 18 months |
| Expected return | 2.3–3.8× on $2.1M midpoint investment within 36 months |
| Revenue, year 1 | $0.8–1.2M ARR (3–4 deals) |
| Revenue, year 2 | $2.4–3.6M ARR (9–12 deals) |
| Revenue, year 3 | $4.2–6.8M ARR (15–20 deals) |
| Exit criteria | Kill move if fewer than 2 deals ≥$150k ACV close by Month 12 OR if any state privacy statute requiring patient-level consent for de-identified data is enacted before Month 18; reallocate remaining budget to Clinical Coaching Capacity Marketplace node |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 组织对齐模型, one of 29 engagements the platform runs. For 数字健康公司 it works through at-risk revenue share, engagement rate, gross margin and logo churn, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
先转移关系，再决策，最后知识。顺序重要，因为关系转移耗时最长，且在任何出售中价值最高。
显著，通过倍数而非收益。买方在为你的离开后仍存续的部分定价，因此依赖你的利润会被大幅折价或排除。
在他们将拥有的决策已定义后。聘用一人来弄清这些决策，通常以所有者完成工作并为此支付双倍费用结束。
Materially, yes. Outcomes risk is being signed faster than the company can learn whether it can carry it — a 12-month measurement window against an 11-month sales cycle — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are at-risk revenue share, engagement rate, gross margin, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on at-risk revenue share and engagement rate. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Svenska · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית